# A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-randomized-phase-2b-trial-of-baricitinib-an-oral-janus-kinase-scp-jak-scp-1/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Kim Papp,Alan Menter,Maitreyi Raman,Damon Disch,D. Schlichting,C. Gaich,William L. Macias,X. Zhang,Jonathan Janes |
| Citations | 261 |
| DOI | 10.1111/bjd.14403 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1111/bjd.14403 |
| OpenAlex ID | https://openalex.org/W2336399478 |
| PMID | 26800231 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Maitreyi Raman](https://scholariq.org/researchers/maitreyi-raman/)

## Paper journal

- [British Journal of Dermatology](https://scholariq.org/journals/british-journal-of-dermatology/)

## Paper primary topic

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

## Paper topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.